stockrowEdwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.
- Revenue
- +10.5%
- EPS
- +6.00%
- Free cash flow
- −1.84%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
Follow EW
Alert me
Edwards Lifesciences Corporation (EW) EPS (diluted)
Edwards Lifesciences Corporation's EPS (diluted) for fiscal 2025 was $1.83, down 73.7% from $6.97 in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.77. Over the past ten years it has ranged from $0.75 (fiscal 2015) to $6.97 (fiscal 2024); the current reading is higher than 64% of that period. Edwards Lifesciences Corporation ranks 22nd of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.83 | (73.74%) |
| FY2024 | $6.97 | 203.04% |
| FY2023 | $2.30 | (5.74%) |
| FY2022 | $2.44 | 2.52% |
| FY2021 | $2.38 | 83.08% |
| FY2020 | $1.30 | (20.89%) |
| FY2019 | $1.64 | 45.85% |
| FY2018 | $1.13 | 17.36% |
| FY2017 | $0.96 | 10.34% |
| FY2016 | $0.87 | 16.00% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.53 | 26.19% |
| Jun 2026 | $0.42 | (36.36%) |
| Mar 2026 | $0.66 | 312.50% |
| Dec 2025 | $0.16 | (68.00%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| SYK Stryker Corporation compare | $9.39 |
| STE STERIS plc compare | $8.43 |
| GEHC GE HealthCare Technologies Inc. compare | $4.76 |
| MDT Medtronic PLC compare | $4.06 |
| ZBH Zimmer Biomet Holdings, Inc. compare | $3.96 |
| DXCM DexCom, Inc. compare | $2.55 |
| BSX Boston Scientific Corporation compare | $2.36 |
| EW Edwards Lifesciences Corporation | $1.77 |
| PHG Koninklijke Philips N.V. compare | $1.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on EW
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement